Geneva, April 20 -- International Clinical Trials Registry received information related to the study (NCT07516951) titled 'A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis' on April 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Chiesi Farmaceutici S.p.A.
Condition:
Idiopathic Pulmonary Fibrosis
Intervention:
Drug: CHF10067
Drug: CHF10067
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: June 1, 2026
Target Sample Size: 240
To know more, vi...